Crolom®

Cochrane review of 30 randomized trials and 4344 participants concluded that topical antihistamines and mast cell stabilizers as a class, sodium cromoglycate among the drugs evaluated, reduce symptoms and signs of seasonal allergic conjunctivitis versus placebo in the short term, with no long term efficacy data and highly variable reporting quality. A comparative review of the seasonal trials notes that cromoglycate eye drops did not control breakthrough symptoms during peak pollen challenge.